FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280491083> ?p ?o ?g. }

• W4280491083 endingPage "1046" @default.
• W4280491083 startingPage "1033" @default.
• W4280491083 abstract "Previous studies had limited power to assess the associations of testosterone with aggressive disease as a primary endpoint. Further, the association of genetically predicted testosterone with aggressive disease is not known. We investigated the associations of calculated free and measured total testosterone and sex hormone-binding globulin (SHBG) with aggressive, overall and early-onset prostate cancer. In blood-based analyses, odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression from prospective analysis of biomarker concentrations in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (up to 25 studies, 14 944 cases and 36 752 controls, including 1870 aggressive prostate cancers). In Mendelian randomisation (MR) analyses, using instruments identified using UK Biobank (up to 194 453 men) and outcome data from PRACTICAL (up to 79 148 cases and 61 106 controls, including 15 167 aggressive cancers), ORs were estimated using the inverse-variance weighted method. Free testosterone was associated with aggressive disease in MR analyses (OR per 1 SD = 1.23, 95% CI = 1.08-1.40). In blood-based analyses there was no association with aggressive disease overall, but there was heterogeneity by age at blood collection (OR for men aged <60 years 1.14, CI = 1.02-1.28; Phet = .0003: inverse association for older ages). Associations for free testosterone were positive for overall prostate cancer (MR: 1.20, 1.08-1.34; blood-based: 1.03, 1.01-1.05) and early-onset prostate cancer (MR: 1.37, 1.09-1.73; blood-based: 1.08, 0.98-1.19). SHBG and total testosterone were inversely associated with overall prostate cancer in blood-based analyses, with null associations in MR analysis. Our results support free testosterone, rather than total testosterone, in the development of prostate cancer, including aggressive subgroups." @default.
• W4280491083 created "2022-05-22" @default.
• W4280491083 creator A5000350877 @default.
• W4280491083 creator A5006860546 @default.
• W4280491083 creator A5009120205 @default.
• W4280491083 creator A5010401322 @default.
• W4280491083 creator A5011703930 @default.
• W4280491083 creator A5011970350 @default.
• W4280491083 creator A5015994795 @default.
• W4280491083 creator A5016405051 @default.
• W4280491083 creator A5017612596 @default.
• W4280491083 creator A5019133187 @default.
• W4280491083 creator A5024041740 @default.
• W4280491083 creator A5027838123 @default.
• W4280491083 creator A5031594786 @default.
• W4280491083 creator A5033124357 @default.
• W4280491083 creator A5038373228 @default.
• W4280491083 creator A5038804932 @default.
• W4280491083 creator A5039379417 @default.
• W4280491083 creator A5041918436 @default.
• W4280491083 creator A5042052338 @default.
• W4280491083 creator A5043960846 @default.
• W4280491083 creator A5046761446 @default.
• W4280491083 creator A5046890841 @default.
• W4280491083 creator A5047212574 @default.
• W4280491083 creator A5047713366 @default.
• W4280491083 creator A5048196698 @default.
• W4280491083 creator A5049753330 @default.
• W4280491083 creator A5051995740 @default.
• W4280491083 creator A5053074659 @default.
• W4280491083 creator A5053483719 @default.
• W4280491083 creator A5054621956 @default.
• W4280491083 creator A5055374455 @default.
• W4280491083 creator A5056390607 @default.
• W4280491083 creator A5057444628 @default.
• W4280491083 creator A5060136612 @default.
• W4280491083 creator A5061697748 @default.
• W4280491083 creator A5063253944 @default.
• W4280491083 creator A5063459619 @default.
• W4280491083 creator A5064532620 @default.
• W4280491083 creator A5067052917 @default.
• W4280491083 creator A5069226602 @default.
• W4280491083 creator A5069531414 @default.
• W4280491083 creator A5070118644 @default.
• W4280491083 creator A5071517509 @default.
• W4280491083 creator A5072420085 @default.
• W4280491083 creator A5073405229 @default.
• W4280491083 creator A5074281181 @default.
• W4280491083 creator A5074815814 @default.
• W4280491083 creator A5076018363 @default.
• W4280491083 creator A5076143455 @default.
• W4280491083 creator A5078854117 @default.
• W4280491083 creator A5079122854 @default.
• W4280491083 creator A5079162702 @default.
• W4280491083 creator A5083450375 @default.
• W4280491083 creator A5084002246 @default.
• W4280491083 creator A5084578086 @default.
• W4280491083 creator A5085935506 @default.
• W4280491083 creator A5088761090 @default.
• W4280491083 creator A5089054506 @default.
• W4280491083 creator A5089976309 @default.
• W4280491083 creator A5091275703 @default.
• W4280491083 creator A5091754121 @default.
• W4280491083 date "2022-06-07" @default.
• W4280491083 modified "2023-10-17" @default.
• W4280491083 title "Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia" @default.
• W4280491083 cites W1596025924 @default.
• W4280491083 cites W1956569991 @default.
• W4280491083 cites W1985298987 @default.
• W4280491083 cites W1991938926 @default.
• W4280491083 cites W2001111773 @default.
• W4280491083 cites W2012608816 @default.
• W4280491083 cites W2032356714 @default.
• W4280491083 cites W2066187800 @default.
• W4280491083 cites W2077833546 @default.
• W4280491083 cites W2098247759 @default.
• W4280491083 cites W2105899460 @default.
• W4280491083 cites W2109600717 @default.
• W4280491083 cites W2134973552 @default.
• W4280491083 cites W2139893960 @default.
• W4280491083 cites W2155530804 @default.
• W4280491083 cites W2160699421 @default.
• W4280491083 cites W2164630495 @default.
• W4280491083 cites W2274299408 @default.
• W4280491083 cites W2312472528 @default.
• W4280491083 cites W2316831615 @default.
• W4280491083 cites W2324862792 @default.
• W4280491083 cites W2508534964 @default.
• W4280491083 cites W2524078243 @default.
• W4280491083 cites W2528302205 @default.
• W4280491083 cites W2545704016 @default.
• W4280491083 cites W2579779633 @default.
• W4280491083 cites W2605070587 @default.
• W4280491083 cites W2614566443 @default.
• W4280491083 cites W2731671395 @default.
• W4280491083 cites W2742787498 @default.
• W4280491083 cites W2777990653 @default.
• W4280491083 cites W2781138582 @default.

• next